Psoriatic Arthritis screening and treatment by Dermatological practitioner
Completed
- Conditions
- MODERATE TO SEVERE PSORIASISPsoriatic ArthropathyArthropathic psoriasisL40.5
- Registration Number
- DRKS00017002
- Lead Sponsor
- AbbVie Deutschland GmbH & Co. KG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 407
Inclusion Criteria
Adult patients >= 18 years
- Moderate to severe plaque-psoriasis
- Currently on systemic psoriasis treatment
- Either suspicion of joint involvement or diagnosed PsA
Exclusion Criteria
- Patients with non-plaque psoriasis
- Patients not on systemic treatment
- Patients not willing or able to give written informed consent
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie psoriatic arthritis development in patients with moderate to severe psoriasis?
How does dermatological practitioner-led screening compare to rheumatologist-led approaches in identifying psoriatic arthropathy cases?
Which biomarkers are most predictive of response to psoriatic arthritis treatment in L40.5 disease subtype patients?
What are the long-term safety profiles of biologic therapies for psoriatic arthropathy in AbbVie-sponsored observational studies?
How do IL-23 inhibitors compare to TNF-alpha blockers in managing arthropathic psoriasis according to recent clinical evidence?